Antisoma's ASA404 programme to expand with new pivotal trial in lung cancer
ATTRACT-2 study will evaluate ASA404 as second-line treatment
Glyn Edwards, Antisoma's CEO, said: "We're very pleased to see Novartis expanding the ASA404 development programme to explore the drug's potential to benefit second-line as well as first-line lung cancer patients. Since there is a clear need for improved treatment options in the second-line setting, we believe this represents a substantial additional opportunity for ASA404."
ATTRACT-2 has been designed to support potential applications to market ASA404 for the second-line treatment of NSCLC. The primary endpoint of the trial will be overall survival. There will be a single interim look before the final analysis. ATTRACT-2 will be a randomised, double-blind, placebo-controlled, multi-centre, multi-country phase III trial including approximately 900 patients receiving their second treatment for stage IIIb/IV NSCLC. Patients will be randomly assigned to receive either ASA404 1800 mg/m2 plus docetaxel or a placebo plus docetaxel.
ASA404 (DMXAA) is a small-molecule Tumour-Vascular Disrupting Agent (Tumour-VDA) which targets the blood vessels that nourish tumours. The drug was discovered by Professors Bruce Baguley and William Denny and their teams at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand. It was in-licensed by Antisoma from Cancer Research Ventures Limited (now Cancer Research Technology), the development and commercialisation company of the Cancer Research Campaign (now Cancer Research UK), in August 2001. Worldwide rights to the drug were licensed to Novartis AG in April 2007.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.